FDA clears Siemens' Biograph mCT PET/CT features
The FDA has cleared features associated with Siemens Healthcare's Biograph mCT PET/CT scanner, which can measure metabolic processes and data quantification, including the assessment of neurological disease, cancerous tissue and cardiac blood flow.

The Biograph mCT offers reproducible quantification in PET/CT imaging by ensuring optimization of each element in the imaging chain, daily system calibration, attenuation correction using automated co-registration algorithms, as well as user-independent and reproducible standardized uptake value (SUV) calculation methods for daily clinical practice, according to the Malvern, Pa.-based company.

The new Biograph mCT incorporates Siemens’ OptisoHD (High-Definition) detector system, which features volumetric resolution of 87 mm. Other technologies include Time of Flight and HD•PET.

Siemens Molecular & Anatomical Registration Technologies (SMART) address the scanner drift and inaccurate attenuation correction through misregistration of anatomical and functional images. Siemens said the system features Auto Cardiac Registration that aligns CT and PET heart images and reduces variability between users. Additionally, SMART offers a new form of attenuation correction for neurological images that no longer requires CT data.

Advanced syngo clinical applications provide tools to obtain quantifiable measurements in neurology, cardiology and oncology imaging. SUVpeak, new in the syngo.via oncology engine, provides reproducible quantitative assessments of hot spots. Myocardial blood flow can be used as an absolute quantification method to assess balanced disease in all areas of the heart. Additionally, a new quantitative tool in neurology–the syngo.PET Neuro DB Comparison application as part of the syngo.mCT Neurology engine–registers brain data to a FDG PET normal database to aid in the assessment of neurological disorders.

The new Biograph mCT is expected to ship in May 2012.